Company Overview

Insulet Corporation is an innovative medical device company based in Acton, Massachusetts, founded in 2000 with the mission of improving the lives of people with diabetes. The company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Trading on NASDAQ under the ticker symbol PODD, Insulet has established itself as a leader in the medical device sector, specifically in diabetes management solutions.

Business Focus & Products

Core Products

The company's Omnipod platform includes the Omnipod 5 automated insulin delivery system, featuring a proprietary Automated Insulin Delivery (AID) algorithm embedded in the pod that integrates with third-party continuous glucose monitors (CGMs) via wireless Bluetooth. It also offers the Omnipod DASH insulin management system, which utilizes a Bluetooth-enabled pod controlled by a smartphone-like personal diabetes manager.

Key Product Features

The Omnipod system distinguishes itself in the diabetes care market through its tubeless design. The disposable Pod offers up to three days of continuous insulin delivery, eliminating the need for visible needles. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system integrated with a CGM. It manages blood sugar without multiple daily injections or fingersticks and can be fully controlled by a compatible personal smartphone (in the U.S.) or by the Omnipod 5 Controller.

Market Expansion

A significant milestone occurred in 2024 when Omnipod 5 received FDA clearance for type 2 diabetes. This made it the first automated insulin delivery system approved for both type 1 and type 2 diabetes, substantially expanding the addressable market for Insulet's products.

Financial Performance

Market Capitalization

As of September 2025, Insulet Corporation has a market capitalization of $23.29 Billion.

Revenue Growth

In 2024, Insulet's revenue reached $2.07 billion, representing a 22.07% increase compared to the previous year's $1.70 billion. This marked the 9th consecutive year of 20% or more constant currency revenue growth and the first year annual revenue surpassed $2 billion.

Recent Quarterly Performance (Q3 2024)

The company demonstrated strong performance in Q3 2024:

- Total Revenue: $543.9 million, up 25.7% year-over-year.

- Total Omnipod Revenue: Increased 26.4% to $533.6 million.

- U.S. Omnipod Revenue: Up 23.4% to $395.6 million.

- International Omnipod Revenue: Up 36.1% to $138.0 million.

- Gross Margin: 69.3%

- Operating Income: $88.1 million

- Net Income: $77.5 million or $1.08 per diluted share.

Key Financial Metrics

- EBITDA: $509.30 Million USD

- EBITDA Margin: 18.81%

- Dividends: PODD does not currently pay dividends to its shareholders.

Business Operations

Distribution Channels

Insulet sells its products directly to end-users through the pharmacy channel and also works with independent distributors. This dual-channel strategy aims to maximize market reach and customer accessibility.

Additional Product Lines

Beyond diabetes care, Insulet also provides pods for Amgen, utilized in the Neulasta Onpro kit. This kit is a delivery system designed to help reduce the risk of infection following intensive chemotherapy.

Recent Developments & Leadership

Leadership Changes

Insulet Corporation has announced significant leadership appointments. Eric Benjamin has been promoted to Chief Operating Officer, overseeing growth and innovation across new products, markets, and commercial expansion. Manoj Raghunandanan joins as Chief Growth Officer, bringing over 20 years of global consumer health leadership experience from Kenvue.

Innovation & Technology

Key accomplishments include collecting 7.4 million Pods through global takeback programs. The company has also expanded international access to Omnipod 5 through integration with Abbott's FreeStyle Libre 2 Plus and Dexcom G7 sensors. Insulet launched the Omnipod 5 App for iPhone and introduced "Insulet for Good," a global corporate giving program that exceeded employee engagement goals.

Sustainability Initiatives

Insulet Corporation's 2024 Sustainability Report highlights significant ESG achievements. The company met 11% of its global electricity needs with renewable energy and installed over 5,700 solar panels at its Malaysia facility, covering 21% of that facility's electricity requirements.

Employee Base

As of September 22, 2025, Insulet Corporation has approximately 3,900 employees.

Insulet Corporation represents a compelling investment opportunity in the growing diabetes care market, driven by its innovative tubeless insulin delivery technology, strong financial performance, and expanding market presence across both type 1 and type 2 diabetes segments.